A sense of community and a love for gardening that’s lasted decades at our U.S. headquarters
Discover our longstanding love for gardening and how it started with Schatzi’s chives.
Search
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live
Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.
Black innovators contribution to health & wellness throughout the years
Read about the many contributions Black innovators have made throughout history and how they continue to shape scientific discoveries today.
Focus on Alliance Management
Focus on Alliance Management
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Ensuring Global Access to Corona Care | Boehringer Ingelheim US
BI has signed a communiqué with the Bill & Melinda Gates Foundation and 15 other companies committing to provide access to COVID-19 related services.
Fremont, California
Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Romy's Third-generation Japanese American Journey
Romy's Third-generation Japanese American Journey
Leadership insights about our focus on patient centricity
Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
Patient Centricity
Patient Centricity
Biberach
Click here to view our Biberach site, in Southern Germany, home to the largest research & development center within Boehringer Ingelheim’s global network.
Sunshine Act Compliance
Sunshine Act Compliance
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Carolina Valoyes | Boehringer Ingelheim Careers
Carolina Valoyes talks about her career in the Quality division and what is next for her in the company.
Giving Back to Those Who Serve Our Country
Giving Back to Those Who Serve Our Country
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut
Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center